A categorization of metal anticancer compounds based on their mode of action.
about
The path for metal complexes to a DNA targetThe mode of action of anticancer gold-based drugs: a structural perspectiveThe X-ray structure of the complex formed in the reaction between oxaliplatin and lysozymeKinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents.Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles.Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSOrganometallic anticancer compoundsSynthesis, characterization, interaction with DNA and cytotoxicity of Pd(II) and Pt(II) complexes containing pyridine carboxylic acid ligands.UV laser photoactivation of hexachloroplatinate bound to individual nucleobases in vacuo as molecular level probes of a model photopharmaceutical.Effect of cobalt(II) chloride hexahydrate on some human cancer cell linesRuthenium(II) polypyridyl complexes and DNA--from structural probes to cellular imaging and therapeutics.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds.Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo.Heteroleptic arene Ru(II) dipyrrinato complexes: DNA, protein binding and anti-cancer activity against the ACHN cancer cell line.A survey of the mechanisms of action of anticancer transition metal complexes.Electrochemical analysis of a novel ferrocene derivative as a potential antitumor drug.Two novel BODIPY-Ru(ii) arene dyads enabling effective photo-inactivation against cancer cells.Fine control on the photochemical and photobiological properties of Ru(II) arene complexes.Fusion of photodynamic therapy and photoactivated chemotherapy: a novel Ru(II) arene complex with dual activities of photobinding and photocleavage toward DNA.Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity.Detailed analysis of pro-apoptotic signaling and metabolic adaptation triggered by a N-heterocyclic carbene-gold(I) complex.Beyond platinum: synthesis, characterization, and in vitro toxicity of Cu(II)-releasing polymer nanoparticles for potential use as a drug delivery vector.A comparative study of in vitro cytotoxic, antioxidant, and antimicrobial activity of Pt(II), Zn(II), Cu(II), and Co(III) complexes with N-heteroaromatic Schiff base (E)-2-[N'-(1-pyridin-2-yl-ethylidene)hydrazino]acetate.Synthesis and characterization of a novel o-tolyltelluronic trimethyltin ester and its cytotoxic assessment in vitro.Factors that influence the antiproliferative activity of half sandwich Ru(II)-[9]aneS3 coordination compounds: activation kinetics and interaction with guanine derivatives.New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.Synthesis and in vitro anticancer activity of ruthenium-cymene complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands.Synthesis, structures, cellular uptake and apoptosis-inducing properties of highly cytotoxic ruthenium-Norharman complexes.An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancer.The antimicrobial activity of inert oligonuclear polypyridylruthenium(II) complexes against pathogenic bacteria, including MRSA.Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways.Reactivity of hexanuclear ruthenium metallaprisms towards nucleotides and a DNA decamer.Metallomics for drug development: an integrated CE-ICP-MS and ICP-MS approach reveals the speciation changes for an investigational ruthenium(III) drug bound to holo-transferrin in simulated cancer cytosol.Stability and structure of mixed-ligand metal ion complexes that contain Ni2+, Cu2+, or Zn2+, and Histamine, as well as adenosine 5'-triphosphate (ATP4-) or uridine 5'-triphosphate (UTP(4-): an intricate network of equilibria.Tuning the cytotoxicity of ruthenium(ii) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand.
P2860
Q26999667-EE8F2793-45EE-42DB-B028-C6ACD9FA5183Q27686705-BC4B7B7D-9B6A-45FC-95E2-687B724E7C1FQ27690763-35D4A8C2-E614-4FFF-B057-98395CA1A3F6Q30670864-53552332-A335-422E-929C-3C25FDA0C999Q33862903-B6258731-60CD-40E9-B682-6CCBF13FE0DEQ33991566-6D63DD05-9321-4995-8375-46223AC0F677Q34394993-5DC71348-1050-429C-8595-795B669C43C9Q34476685-9B00AC1F-B2F6-4D19-839D-2C5E1AEB4FBBQ34555057-8546A342-F4E2-42EA-95C8-98AB63BA3115Q36023114-504B3594-5F20-4DEA-B0B9-4E5E553D6890Q37056611-BC755784-EEC9-420D-BA90-AB5C7E7DBBB1Q37982323-2C17E85C-FEEC-4E81-919E-C6677037CF7FQ38096196-C9CE237D-DD3F-40EA-A46C-B9A8A722F2F8Q38162354-D0402D7B-6B27-4D2E-A805-86C1AF8D651AQ38289334-3AED6ED5-4149-45F5-83DA-BD32887A48A1Q38699445-BC47DD46-94C7-472E-9E7F-CB8EF57566A7Q38781054-A7913230-28A5-4186-9863-5AFD99E2FF43Q38783737-FDFD319E-4967-4FDB-A57A-E0334019E05BQ38792102-2AD90D88-B150-4216-903B-7E3C1A140022Q38850101-46A150A1-C489-491A-937B-2404D100E1A3Q38862566-AE14B4C5-0D9F-4FBB-8EC6-A9250C7B391BQ38896587-638BE6C1-6E8C-4800-93E4-D83C8C17766EQ38959861-E98A0C9C-C977-4469-94A3-4FD74ABAB194Q39000218-54EA1B04-1F19-4F39-AEC1-94D128814E93Q39000649-EA4E464A-86AC-4F94-A849-766974465EE5Q39002265-DB957635-7214-42DD-B152-7EBD856EF4EFQ39049578-6D5E9E42-3542-4A9F-8E98-002A349CCE78Q39076226-0CB10AE5-09F4-4A3B-A09A-820D5AF28935Q39295123-0596B608-9383-4940-B15E-F8FF4FFFB7FBQ39488143-E9D60310-B593-42C8-A40A-8DC0CC208A8CQ39497208-C3066E5A-4FB4-4D6F-804C-A3AF4F351582Q39497573-4CCFE4EF-7582-4FF9-96C5-AD66B68C2695Q39515682-84BB1EE1-10BA-47DF-A3B6-BF1252AEE16AQ39569670-03FA2AB6-B5D1-4A0F-BE8F-8D82C3CEAA8DQ39576903-A0B639DE-725E-4559-BC17-F1C6318C28FCQ44340767-27621E23-5615-4603-8D88-FA2E353747BCQ45835320-214CB050-3E9C-4A9B-91F5-A6332036C8C2Q45968243-CDA5F04E-BF34-46E6-93A4-E93BA0287F47Q46169112-6E2D8FDB-4267-456E-8CCA-75E333C2D3CCQ46256422-97CE275F-B0D7-44F7-B0BB-A42C482DA83E
P2860
A categorization of metal anticancer compounds based on their mode of action.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A categorization of metal anticancer compounds based on their mode of action.
@en
A categorization of metal anticancer compounds based on their mode of action.
@nl
type
label
A categorization of metal anticancer compounds based on their mode of action.
@en
A categorization of metal anticancer compounds based on their mode of action.
@nl
prefLabel
A categorization of metal anticancer compounds based on their mode of action.
@en
A categorization of metal anticancer compounds based on their mode of action.
@nl
P356
P1433
P1476
A categorization of metal anticancer compounds based on their mode of action.
@en
P2093
Teresa Gianferrara
P304
P356
10.1039/B905798F
P407
P577
2009-06-05T00:00:00Z